Omega Therapeutics

Cambridge, United States Founded: 2016 • Age: 10 yrs Listed
Platform for human genome study is provided for precision medicine.

About Omega Therapeutics

Omega Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2016 by David Berry. Platform for human genome study is provided for precision medicine. Omega Therapeutics has raised $211 million across 3 funding rounds from investors including Fidelity Investments, Mirae Asset and BlackRock. The company has 93 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is OMEGA THERAPEUTICS, INC. Its competitors include Denali Therapeutics, MiRagen and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Omega Therapeutics was founded in 2016 and is based in Cambridge, United States. A proprietary platform known as GenomStats is employed to regulate genomic expression without modifying nucleic acid sequences. Focus is placed on precision medicine applications for rare genetic diseases, immunology, inflammation, metabolic disorders, and oncology. Operations center on advancing therapeutic solutions in the biotechnology sector.

  • Headquarters Cambridge, United States
  • Employees 93
  • Founders David Berry
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website omegatherapeutics.com
  • Social LinkedIn X
  • Legal Name Omega Therapeutics, Inc.
Key Metrics
  • Annual Revenue
    $3.09 M (USD)
    49
    as on Dec 31, 2023
  • Net Profit
    -$97.43 M (USD)
    5
    as on Dec 31, 2023
  • EBITDA
    -$100.26 M (USD)
    2
    as on Dec 31, 2023
  • Total Equity Funding
    $211M (USD)

    in 3 rounds

  • Latest Funding Round
    $126M (USD), Series C

    Mar 2021

  • Investors
  • Employee Count
    93

Funding Insights of Omega Therapeutics

Omega Therapeutics has successfully raised a total of $211M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $126 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $211M
  • Total Rounds 3
  • Last Round Series C β€” $126M
  • Investors Count 8

All 3 funding rounds of Omega Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$126MSeries C–Invus, Logos
–
Jul 2020$85MSeries B–Flagship Pioneering
Jun 2016Series A––
–
Valuation history

8 investors in total: 8 institutional.

Investors in Omega Therapeutics

Omega Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Mirae Asset and BlackRock.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Long-term private equity investments in transformational opportunities are pursued.
invus.comNew York, United States
Private equity fund focused on the biotechnology sector
logoscapital.comSan Francisco, United States
Life sciences-focused venture capital firm
1999flagshippioneering.comCambridge, United States
Manages alternative investments through equity, systematic, macro, and private strategies worldwide.
2014point72.comStamford, United States
Corporate finance advisory, mergers, acquisitions, and investment services are provided.
1918cowen.comNew York, United States
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
1946fidelity.comBoston, United States
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors
1988blackrock.comNew York, United States
Mirae Asset Financial Group is engaged in global investment and financial services.
1997miraeasset.comSeoul, South Korea
Premium access

Investor details for Omega Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Omega Therapeutics

10 people are tracked at Omega Therapeutics (3 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 93.

NameRoleGroup
David Berry
Co-FounderLeadership
Benjamin Frempah
Director, Business DevelopmentLeadership
Justin Chen
DirectorLeadership
Rainer Boehm
DirectorBoard & advisors
Rick Young
DirectorBoard & advisors
Noubar Afeyan
Chairman & FounderBoard & advisors
John Mendlein
DirectorBoard & advisors
Elliott M. Levy
DirectorBoard & advisors
Paul Aborn
Senior Manager, Accounting OperationsTeam
Daniel Costa
Sr. Scientist, Formulation And Drug DeliveryTeam
Premium access

Complete people profiles for Omega Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Omega Therapeutics

4 dated milestones of Omega Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Omega Therapeutics is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series C, of $126.0M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Omega Therapeutics

Omega Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Poseida Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
denalitherapeutics.com2015San Francisco, United States$347M377
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
miragen.com2007Boulder, United States$111.29M92
MicroRNA-based therapeutics are developed for treating multiple diseases.
poseida.com2015San Diego, United States$323.78M259
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
Premium access

Detailed competitors of Omega Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Omega Therapeutics

Websites that share an audience with Omega Therapeutics (omegatherapeutics.com).

Similar websites

Websites whose visitors overlap most with Omega Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pharmavoice.com
pharmavoice.com
100%
#720,985–
flagshippioneering.com
95%
73.9K#540,577View details
fiercebiotech.com
76%
858.3K#81,022View details

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Omega Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Omega Therapeutics

Premium access

Complete news archive for Omega Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Omega Therapeutics

Omega Therapeutics was founded in 2016.

Omega Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Omega Therapeutics is a funded company, having raised a total of $211M across 3 funding rounds to date.

Omega Therapeutics has 93 employees.

Annual revenue of Omega Therapeutics is $3.09M as on Dec 31, 2023.

Omega Therapeutics was founded in 2016 and is based in Cambridge, United States. A proprietary platform known as GenomStats is employed to regulate genomic expression without modifying nucleic acid sequences. Focus is placed on precision medicine applications for rare genetic diseases, immunology, inflammation, metabolic disorders, and oncology. Operations center on advancing therapeutic solutions in the biotechnology sector.

Omega Therapeutics's top competitors include Poseida Therapeutics, Denali Therapeutics and MiRagen.

Omega Therapeutics has 8 investors. Key investors include Fidelity Investments, Mirae Asset, BlackRock, TD Securities, and Flagship Pioneering.

Omega Therapeutics operates through Omega Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available